secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2024-11-21T23:59:59+00:00
Accession:  0001104659-24-121533
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CAMP4 reports Q3 net loss $13.5M, completes IPO raising $82.1M, and signs BioMarin collaboration
--------------------------------------------------------------------------------

- Q3 net loss $13.5M vs $11.7M in prior year; R&D $9.7M, G&A $3.8M.
- Completed IPO in Oct 2024: 6.82M shares at $11.00, gross proceeds $82.1M (including partial underwriter option).
- Entered strategic research collaboration with BioMarin valued at over $370M in milestones and royalties.
- Phase 1 SAD portion completed; safety data expected Q1 2025, MAD biomarker data in H2 2025.
- Cash $2.5M as of Sep 30, 2024; pro forma with IPO proceeds well-positioned to support development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000110465924121533/0001104659-24-121533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000110465924121533/tm2428967d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-121533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer